Colinz Laboratories

Colinz Laboratories EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Colinz Laboratories (531210.BO) as of Nov 3, 2026 is 60.58. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 41.84 — a change of 44.81% (higher).

EV/EBIT

60.58

YoY

44.81%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Colinz Laboratories is 2026 60.58 . EV/EBIT (Enterprise Value to EBIT) of Colinz Laboratories was 2025 41.84 . It decreases by 44.81% higher compared to the previous year.

The Colinz Laboratories EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
112.95 INR
Jan 1, 2020
141.05 INR
Jan 1, 2021
108.26 INR
Jan 1, 2022
39.54 INR
Jan 1, 2023
30.22 INR
Jan 1, 2024
36.19 INR
Jan 1, 2025
41.84 INR
Jan 1, 2026
60.58 INR
The Colinz Laboratories EV/EBIT history
YEAREV/EBITYoY
60.58+44.81%
41.84+15.61%
36.19+19.73%
30.22-23.57%
39.54-63.47%
108.26-23.24%
141.05+24.87%
112.95+2.06%
110.68+4.90%
105.51+17.29%
89.95-7.42%
97.16-10.69%
108.79+2,161.82%
4.81-59.68%
11.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Colinz Laboratories's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Colinz Laboratories's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Colinz Laboratories's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Colinz Laboratories grows earnings faster than its peers.

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd manufactures pharmaceutical formulations including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company markets allopathic and ayurvedic products targeting hypertension, cholesterol, diabetes, piles, pyrexia, and malaria treatments for physicians. Gynecologists receive specialized products for morning sickness, infertility, IUGR, and pregnancy maintenance. Additional offerings include hematinic, antispasmodic, anti-inflammatory/anti-allergic tablets, capsules, gel, and medicated shampoo. Products are sold across Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal through the company's own marketing team. The firm's revenue streams come from direct sales to healthcare professionals and pharmacies within its operational states. Physicians prescribe products for chronic conditions like hypertension and diabetes, while gynecologists utilize specialized treatments for pregnancy-related issues. The company's product portfolio spans both conventional allopathic medicines and traditional ayurvedic formulations, catering to diverse medical needs. Marketing efforts focus on state-specific distribution through dedicated in-house sales staff. Colinz Laboratories Ltd serves the pharmaceutical market segment with a clear focus on regional healthcare providers. Its product range addresses common health concerns such as cardiovascular issues, metabolic disorders, and pregnancy care. The company's strategy involves direct engagement with medical practitioners to promote its formulations, ensuring consistent market presence in key Indian states without external partnerships or third-party distribution channels. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

EV/EBIT (Enterprise Value to EBIT) of Colinz Laboratories is 60.58 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Colinz Laboratories changed from 41.84 to 60.58, representing a 44.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Colinz Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Colinz Laboratories

All Key Metrics — Colinz Laboratories